Alnylam Pharmaceuticals, Inc.

ALNYintermediary

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($2.4B)

Static data (loading live financials…)

ATTR Franchise (Amvuttra/Onpattro) (65%)

Royalties & Collaboration (Leqvio) (25%)

Other Pipeline Revenue (10%)

Segment Breakdown & Key Customers

Product Details

Onpattro (Patisiran)30%

First FDA-approved RNAi therapeutic for hereditary ATTR amyloidosis

Amvuttra (Vutrisiran)40%

Subcutaneous RNAi treatment for ATTR polyneuropathy (quarterly dosing)

Leqvio (Inclisiran)30%

RNAi cholesterol-lowering drug partnered with Novartis

Supply Chain Relationships

Partners

Regeneron Pharmaceuticals

RNAi research collaboration

Impact: Strategic R&D alliance

Eli Lilly and Company

Potential licensing discussions

Impact: Pharma partnership potential

Competitors

Moderna, Inc.

RNA-based therapeutic modalities

Impact: Competing RNA platforms

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Alnylam Pharmaceuticals, Inc..

Company Info

Headquarters

Cambridge, Massachusetts, USA

Founded

2002

Employees

2,800+

Website

alnylam.com

Sector Overview — 제약 / 바이오

Sector News